Kang Chao
Overview
Explore the profile of Kang Chao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
475
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang Z, Wang B, Peng B, Liu Z, Lin H, Yang Q, et al.
World J Gastroenterol
. 2025 Feb;
31(7):98448.
PMID: 39991678
Background: Endoscopic healing (EH) is a key therapeutic target in Crohn's disease (CD). Proximal small bowel (SB) lesions in patients with CD are associated with a significant risk of strictures...
2.
Li Q, Song X, Su P, Lv X, Liu X, Chen X, et al.
Therap Adv Gastroenterol
. 2025 Feb;
18:17562848251321707.
PMID: 39975482
Background: Vedolizumab (VDZ), a humanized monoclonal antibody that selectively inhibits the binding of the α4β7 integrin, has been approved for treating inflammatory bowel disease (IBD). Long-term safety studies of VDZ...
3.
Huang Z, Lin L, Li Q, Wu Y, Jiang T, Sun Z, et al.
Dig Liver Dis
. 2025 Feb;
PMID: 39939201
Background & Aims: The initial intravenous dose of ustekinumab (UST) for treating Crohn's disease (CD) is recommended based on body weight ranges for clinical convenience. However, patients whose body weight...
4.
Jingjing Wu M, Wu J, Lang Lin M, Lin L, Yan J, Jia-Jia Yan M, et al.
J Pharmacol Toxicol Methods
. 2025 Jan;
131:107581.
PMID: 39862900
Background: Upadacitinib is a selective Janus kinase (JAK) 1 inhibitor approved by the Food and Drug Administration for the treatment of moderate-to-severe inflammatory bowel disease (IBD). We aimed to establish...
5.
Wang B, Liu H, Guo Q, Gao X, Chao K, Yang Q
Front Genet
. 2025 Jan;
15:1425062.
PMID: 39744064
Background: Crohn's disease (CD) is an immune-mediated disorder characterized by immune cell infiltration that induces persistent chronic inflammation of the gastrointestinal tract. Programmed cell death (PCD) plays a critical role...
6.
Li Q, Tang J, Huang Z, Shi L, Lyu X, Chen X, et al.
J Dig Dis
. 2024 Dec;
25(9-10):594-602.
PMID: 39710431
Objectives: We aimed to evaluate the effectiveness and safety of clinical decision support tool (CDST)-guided initial selective intensive induction therapy (IIT) for patients with Crohn's disease (CD) who were treated...
7.
Yang Q, Diao N, Ma F, Huang Z, Lin M, Liu X, et al.
Cell Death Dis
. 2024 Dec;
15(12):923.
PMID: 39706833
Lipid metabolism disorder is a critical feature of Crohn's disease (CD). Phosphatidylinositol (PI) and its derivative, phosphatidylinositol bisphosphate (PIP2), are associated with CD. The mechanisms underlying such association remain unknown....
8.
Chen X, Liu W, Liao Y, Xiang X, Yang Y, Tian L, et al.
Environ Health (Wash)
. 2024 Oct;
2(7):453-464.
PMID: 39473886
Microcystin-LR (MC-LR), the most prevalent and diverse cyanotoxin produced by harmful cyanobacterial blooms, has been linked to gastrointestinal toxicity. Therefore, we conducted a case-control study across four regions in China...
9.
Huang Z, Tang J, Wu R, Long S, Chen W, Lu T, et al.
Therap Adv Gastroenterol
. 2024 Oct;
17:17562848241281218.
PMID: 39420999
Background: No head-to-head trial directly compares the effectiveness of vedolizumab (VDZ) and infliximab (IFX) in patients with ulcerative colitis (UC) who were naïve to biologic therapy. Objectives: We aimed to...
10.
Deng X, Lin M, Gao X, Liu X, Wu Y, Chao K, et al.
J Dig Dis
. 2024 Aug;
25(7):444-452.
PMID: 39165118
Objectives: Familial Crohn's disease (CD) accounts for approximately 1.5%-22.5% of all CD cases worldwide. We aimed to assess the concordance in disease subtype and phenotypic features among patients with CD...